Navigation Links
CRG buys Genomatix' Next Generation Sequencing analysis solution
Date:3/4/2009

The Centre for Genomic Regulation (CRG) in Barcelona, Spain purchased the Genomatix Genome Analyzer (GGA), as announced today by Genomatix Software GmbH.

GGA comprises purpose built high performance hardware and terabytes of proprietary databases and software providing a complete solution for the analysis of Next Generation Sequencing (NGS) data after mapping to the genome.

"In regards to the machine, I love it! And I have advertised it to many colleagues," says Dr. Ramin Shiekhattar, Group Leader within the Gene Regulation Programme.

"We are pursuing research in two major areas. The first is the molecular mechanism of cancer. We are working to address the mechanism by which tumor suppressors such as BRCA1 and BRCA2 exerted their biological effects. Our second avenue of research entails the delineation of the mechanisms by which the genome is silenced through chromatin modification and small regulatory RNA. The laboratory's goal is to understand the epigenetic regulation of gene expression in mammalian development and genetic disease"

Klaus May, Chief Business Officer at Genomatix says:" I am extremely excited that one of our installations of the GGA went to the CRG in Barcelona. This is a very impressive institution with outstanding scientists and cutting edge equipment at a wonderful location. Our GGA definitely fits into that environment and will contribute substantially to the analysis of data produced by their sequencers. "

The Genomatix Genome Analyzer (GGA) delivers all downstream tools and databases for deep biological analysis of mapped data coming from next generation sequencers. It allows for easy integration and visualization within the terabytes of background annotation of the most complete mammalian genome annotation: ElDorado. GGA delivers annotation of genomic coordinates from GMS or any other mapping procedure, clustering and peak finding, analysis for phylogenetic conservation, large scale correlation analysis with any annotated genomic elements, meta-analysis of data correlation between different experiments, pathway mining for groups of identified genes, transcription factor binding site (TFBS) analysis (identification, over-representation, binding partner analysis, framework identification, phylogenetic conservation, regulatory SNP effects) and much more.


'/>"/>

Contact: Klaus May
may@genomatix.de
49-895-997-660
Genomatix Software GmbH
Source:Eurekalert

Related biology news :

1. Boehringer Ingelheim uses Genomatix Next Generation Sequencing data analysis systems
2. Genomatix joins Illumina-Connect program
3. Pfizer inks global license to Genomatix Software and databases
4. NIA uses Genomatix in stem cell research, suggests novel transcription factors for stemness
5. Energy drinks: The coffee of a new generation?
6. New generation of orthopedic, dental and cardiovascular prostheses
7. Next generation microscopy: No stain, big gain
8. e-Smart Technologies to Introduce Next Generation I AM Smart Card Technology at Cartes 2008 in Paris
9. Gene therapy restores vision to mice with retinal degeneration
10. Cholesterol-lowering drugs and the effect on muscle repair and regeneration
11. Generation innovation: Young UC San Diego bioengineer to use NIH grant to fuel tissue engineering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...
(Date:12/6/2016)... Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... an offering of €500.0 million principal amount of its 1.414% ... of its 2.425% senior unsecured notes due 2026. ... on December 13, 2016, subject to the satisfaction of customary closing ... The Company intends to use ...
(Date:12/2/2016)... 2016 The report "Biometric Vehicle ... Technology (Iris Recognition System), Vehicle Type (Passenger Car, ... to 2021", published by MarketsandMarkets, the market is ... and is projected to grow to USD 854.8 ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... 8, 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... on developing and commercializing products to treat rare ... announced today the long-term follow-up data from its ... first-in-class Innate Defense Regulator (IDR), in the treatment ... cancer patients undergoing chemoradiation therapy (CRT).  The additional ...
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/7/2016)... ... December 07, 2016 , ... A new study published in ... previously treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute ... of blood sampling may improve the value of a blood-based test.” The study ...
(Date:12/7/2016)... CALGARY , Dec. 7, 2016 /PRNewswire/ - Zenith Capital Corp. ... update that will be presented at the Company,s Annual and ... Meeting of Shareholders will take place on Thursday, December 15, ... Ross Glenn Hall (Room EC1040), 4825 Mount Royal Gate ... am (MST). A notice of meeting and management information circular, ...
Breaking Biology Technology: